Corebridge Financial Inc. decreased its holdings in Haemonetics Co. (NYSE:HAE - Free Report) by 6.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 81,432 shares of the medical instruments supplier's stock after selling 5,543 shares during the period. Corebridge Financial Inc. owned about 0.16% of Haemonetics worth $6,358,000 as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Arizona State Retirement System grew its stake in Haemonetics by 1.2% in the fourth quarter. Arizona State Retirement System now owns 14,853 shares of the medical instruments supplier's stock worth $1,160,000 after purchasing an additional 181 shares in the last quarter. Parkside Financial Bank & Trust grew its position in shares of Haemonetics by 25.6% during the 4th quarter. Parkside Financial Bank & Trust now owns 1,176 shares of the medical instruments supplier's stock worth $92,000 after buying an additional 240 shares in the last quarter. HighTower Advisors LLC increased its stake in shares of Haemonetics by 7.8% during the fourth quarter. HighTower Advisors LLC now owns 3,353 shares of the medical instruments supplier's stock valued at $262,000 after buying an additional 244 shares during the period. Xponance Inc. raised its holdings in shares of Haemonetics by 5.9% in the fourth quarter. Xponance Inc. now owns 7,246 shares of the medical instruments supplier's stock valued at $566,000 after acquiring an additional 404 shares in the last quarter. Finally, Isthmus Partners LLC lifted its stake in Haemonetics by 1.1% in the fourth quarter. Isthmus Partners LLC now owns 40,220 shares of the medical instruments supplier's stock worth $3,140,000 after acquiring an additional 450 shares during the period. Institutional investors own 99.67% of the company's stock.
Haemonetics Stock Performance
NYSE:HAE traded up $0.22 during trading hours on Wednesday, reaching $63.24. The company had a trading volume of 67,790 shares, compared to its average volume of 923,745. The firm has a market cap of $3.18 billion, a PE ratio of 24.90, a price-to-earnings-growth ratio of 1.11 and a beta of 0.43. Haemonetics Co. has a 1-year low of $58.80 and a 1-year high of $97.97. The business's 50 day moving average price is $65.60 and its 200-day moving average price is $74.54. The company has a debt-to-equity ratio of 1.35, a current ratio of 3.97 and a quick ratio of 2.55.
Haemonetics (NYSE:HAE - Get Free Report) last posted its earnings results on Thursday, February 6th. The medical instruments supplier reported $1.19 EPS for the quarter, missing analysts' consensus estimates of $1.20 by ($0.01). Haemonetics had a net margin of 9.47% and a return on equity of 23.66%. Research analysts forecast that Haemonetics Co. will post 4.55 EPS for the current year.
Wall Street Analyst Weigh In
A number of equities analysts recently commented on HAE shares. JPMorgan Chase & Co. started coverage on shares of Haemonetics in a research note on Friday, December 6th. They issued an "overweight" rating and a $116.00 price objective for the company. Barrington Research reduced their price target on Haemonetics from $108.00 to $95.00 and set an "outperform" rating for the company in a research report on Friday, February 7th. Needham & Company LLC dropped their price objective on Haemonetics from $108.00 to $104.00 and set a "buy" rating on the stock in a research report on Tuesday, March 18th. StockNews.com downgraded shares of Haemonetics from a "buy" rating to a "hold" rating in a report on Saturday, February 15th. Finally, Raymond James restated a "strong-buy" rating and issued a $115.00 price target (down from $120.00) on shares of Haemonetics in a report on Friday, February 7th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $101.22.
Get Our Latest Analysis on Haemonetics
About Haemonetics
(
Free Report)
Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.
Featured Stories
Before you consider Haemonetics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Haemonetics wasn't on the list.
While Haemonetics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
